By the end of March beginning of April we should be having a news release about the meetings ALDA will be having with the investment community in Calgary, Edmonton, Toronto, Ottawa and Montreal.

When this news comes out and ALDA secures some big time investors , the sp should rise considerably. Lets hope by then we have the DIN#.

But for now lets batten down the hatches, sit tight and hold on until then, there might be some rough waters ahead.

Here is News release from March 12 2008.

ALDA PHARMACEUTICALS CORP.

635 Columbia Street New Westminster,

British Columbia V3M 1A7

Tel: (604) 521-8300 Fax: (604) 521-8322

NEWS RELEASE

TSX-V SYMBOL: APH March 12, 2008

ALDA FILES 2006 20F WITH SEC Vancouver, BC

- ALDA Pharmaceuticals Corp. (APH:TSX-V, “ALDA”) has completed the filing of its June 30, 2006 20F registration statement on the SEC's EDGAR system. The next step, after receiving comments from the SEC reviewer, will be to file the June 30, 2007 registration statement. Dr. Terrance Owen, President & CEO, states, “We are catching up on our filings with the SEC after a long hiatus while we contemplated our foreign listing strategy.

Management has decided that it is advantageous to continue with the US registration of ALDA’s securities and we plan to move forward as quickly as possible. We also feel this is an appropriate time to present the company to a broader audience.

Accordingly, we will be meeting with selected representatives of the investment community in Calgary, Edmonton, Toronto, Ottawa and Montreal in the next few weeks to discuss ALDA’s progress”. About ALDA Pharmaceuticals

ALDA is focused on the development of infection control therapeutics derived from itspatented T36® technology.

The company trades on the TSX Venture Exchange under thesymbol APH.

Terrance G. Owen, Ph.D., MBAPresident, CEO and Director ALDA Phaits patentedrmaceuthe symbolticMBA Presidentals Corp.www.aldacorp.com

Distribution & Sales Contact Peter Chen(604) 521- 8300 Ext. 3

peter_chen@aldacorp.com.Investor Relations